SCHEMBL425585

SCHEMBL425585

CN(Cc1ccccc1)C(=O)n1cnc(-c2ccc(F)cc2)c1

nearest known ligand 0.57

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
FAAH O00519 1/20 0.57
LMNA P02545 2/20 0.53
TP53 P04637 1/20 0.53
THRB P10828 1/20 0.48
TDP1 Q9NUW8 2/20 0.45
KMT2A Q03164 3/20 0.45
MAPT P10636 2/20 0.45
ALDH1A1 P00352 2/20 0.45
TACR1 P25103 1/20 0.43
APOBEC3A P31941 1/20 0.43
ATM Q13315 1/20 0.42
USP19 O94966 1/20 0.42
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
CA12 O43570 1/20 0.41
CA9 Q16790 1/20 0.41
MEN1 O00255 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14937537 0.83 FAAH (0.58) FAAHLMNAKMT2AALDH1A1APOBEC3A
SCHEMBL425550 0.81 FAAH (0.51) FAAHLMNATP53KMT2AMAPT
SCHEMBL427768 0.77 OPRM1 (0.53) FAAHKMT2AMEN1
SCHEMBL443278 0.76 FAAH (0.54) FAAHLMNATP53KMT2AMAPT
SCHEMBL448626 0.75 FAAH (0.53) FAAHLMNATDP1KMT2AMAPT
SCHEMBL526735 0.74 FAAH (0.65) FAAHLMNAKMT2AMAPTRAB9A
SCHEMBL2181000 0.74 FAAH (0.64) FAAHLMNAKMT2ANPC1RAB9A
SCHEMBL7899731 0.74 FAAH (0.46) FAAHLMNATDP1KMT2AMAPT
SCHEMBL427826 0.74 FAAH (0.49) FAAHLMNATHRBKMT2AMAPT
SCHEMBL424617 0.73 FAAH (0.48) FAAHLMNATHRBTDP1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9353082-B2 Pharmaceutical compounds BIAL—PORTELA & CA, S.A. (PT) 2016-05-31 US disclosed
US-9353082-B2 Pharmaceutical compounds BIAL—PORTELA & CA, S.A. (PT) 2016-05-31 US disclosed
US-9353082-B2 Pharmaceutical compounds BIAL—PORTELA & CA, S.A. (PT) 2016-05-31 US disclosed
US-20120065191-A1 PHARMACEUTICAL COMPOUNDS BIAL - PORTELA & Cª, S.A. (PT) 2012-03-15 US disclosed
US-20120065191-A1 PHARMACEUTICAL COMPOUNDS BIAL - PORTELA & Cª, S.A. (PT) 2012-03-15 US disclosed
US-20120065191-A1 PHARMACEUTICAL COMPOUNDS BIAL - PORTELA & Cª, S.A. (PT) 2012-03-15 US disclosed
WO-2010074588-A2 PHARMACEUTICAL COMPOUNDS BIAL - PORTELA & Cª, S.A. (PT) 2010-07-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120065191-A1 PHARMACEUTICAL COMPOUNDS FAAH, FAAH2, ASAH1 FAAH 1/4885LMNA 2523/4885TP53 4604/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.